I think that these DCVax-L approvals in the rest of the world (ROW), including Asia and Israel, will come very quickly. Especially, if DCVax-L is quickly adopted as a foundational part of the new standard of care (SOC) to treat both ndGBM and rGBM.
I believe that the primary vehicle that will be used for DCVax-L global expansion, will be NWBio’s relationship with Cognate, now Charles River Laboratories (CRL). CRL already has a global footprint, and the knowledge base that Cognate (Memphis) has, can be quickly trained, learned and replicated throughout CRL’s global footprint.
Market Data 
Markets 
AI
